Spyre Therapeutics, Inc. (SYRE) Stock Price & Analysis

Spyre Therapeutics, Inc. (SYRE) rose 1.98% to USD 88.98 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.

SYRE last closed at USD 88.98; the session ranged USD 84.68–89.18 on volume of 803,857 shares. Market capitalization is —, with a 52-week range of USD 14.51–110.18 (NMS). Source: Nexqual, September 8, 2026 at 04:59 UTC.

Key Statistics (as of September 8, 2026 at 04:59 UTC)

Technical Analysis (SYRE)

Nexqual's technical model rates SYRE "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 04:59 UTC.

From Spyre Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• We seek to protect our proprietary information, in part by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants.
• The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
• Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our product candidates.
• Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities.

Partnerships

• With respect to the SPY002 License Agreement only, on a product by product basis, we are obligated to pay sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.
• Paragon Agreement In May 2023, Pre-Merger Spyre entered into the Paragon Agreement with Paragon and Parapyre.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.